Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer

被引:68
|
作者
Zaravinos, Apostolos [1 ,2 ]
Roufas, Constantinos [1 ,3 ]
Nagara, Majdi [4 ]
de Lucas Moreno, Beatriz [1 ,5 ]
Oblovatskaya, Maria [1 ]
Efstathiades, Christodoulos [2 ,3 ]
Dimopoulos, Christos [2 ,3 ]
Ayiomamitis, Georgios D. [6 ]
机构
[1] European Univ Cyprus, Sch Sci, Dept Life Sci, CY-1516 Nicosia, Cyprus
[2] Ctr Risk & Decis Sci CERIDES, CY-2404 Nicosia, Cyprus
[3] European Univ Cyprus, Dept Comp Sci & Engn, CY-1516 Nicosia, Cyprus
[4] Aix Marseille Univ, Fac Med, INSERM, UMR S 1251,MMG, Marseille, France
[5] European Univ Madrid, Ctr Res Hlth & Life Sci, Madrid 28670, Spain
[6] Tzane Gen Hosp, Surg Dept 1, Piraeus 18536, Greece
关键词
Colorectal cancer; Cytolytic activity; Classically defined neoepitopes; Alternatively defined neoepitopes; Mutation burden; Immune checkpoints; Cancer drivers; CD8(+) T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; ANTI-PD-L1; ANTIBODY; GENOMIC INSTABILITY; CLINICAL IMPACT; SOLID TUMORS; COLON; SURVIVAL;
D O I
10.1186/s13046-019-1372-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMicrosatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC's biology, including neoepitope burden.MethodsWe used TCGA data to stratify patients based on a cytolytic T-cell activity expression index and correlated immune cytolytic activity (CYT) with mutational, structural, and neoepitope features of each tumor sample. The expression of several immune checkpoints was verified in an independent cohort of 72 CRC patients, relative to their MSI status, using immunohistochemistry and RT-qPCR.ResultsCRC exhibits a range of intertumoral cytolytic T-cell activity, with lower cytolytic levels in the tumor, compared to the normal tissue. We separated CRC patients into CYT-high and CYT-low subgroups. High cytolytic activity correlated with increased mutational load in colon tumors, the count of MHC-I/-II classically defined and alternatively defined neoepitopes, high microsatellite instability and deregulated expression of several inhibitory immune checkpoints (VISTA, TIGIT, PD-1, IDO1, CTLA-4, and PD-L1, among others). Many immune checkpoint molecules (IDO1, LAG3, TIGIT, VISTA, PD-1, PD-L1 and CTLA-4) expressed significantly higher in MSI+ CRCs compared to MSS tumors. The expression of Treg markers was also significantly higher in CYT-high tumors. Both individual and simultaneous high levels of CTLA-4 and PD-L1 had a positive effect on the patients' overall survival. On the reverse, simultaneous low expression of both genes led to a significant shift towards negative effect. Assessed globally, CYT-low CRCs contained more recurrent somatic copy number alterations. PD-L1 protein was absent in most samples in the independent cohort and stained lowly in 33% of MSI CRCs. PD-L1+ CRCs stained moderately for CD8 and weakly for FOXP3. CYT-high colon tumors had higher TIL load, whereas CYT-high rectum tumors had higher TAN load compared to their CYT-low counterparts.ConclusionsOverall, we highlight the link between different genetic events and the immune microenvironment in CRC, taking into consideration the status of microsatellite instability. Our data provide further evidence that MSI+ and CYT-high tumors are better candidates for combinatorial checkpoint inhibition.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer
    Yoon, Shinkyo
    Kang, Byung Woog
    Park, Su Yeon
    Kim, Hye Jin
    Park, Jun Seok
    Choi, Gyu Seog
    Kim, Jong Gwang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (08) : 1775 - 1780
  • [42] Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis
    Li, Yan
    Ma, Yiqi
    Wu, Zijun
    Zeng, Fanxin
    Song, Bin
    Zhang, Yanrong
    Li, Jinxing
    Lui, Su
    Wu, Min
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [43] Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer
    Gao, Ze
    Tao, Yiran
    Lai, Yiming
    Wang, Qiong
    Li, Zean
    Peng, Shirong
    Chen, Junxiu
    Cai, Wenli
    Li, Kaiwen
    Huang, Hai
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2020, 8
  • [44] Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer
    Shinkyo Yoon
    Byung Woog Kang
    Su Yeon Park
    Hye Jin Kim
    Jun Seok Park
    Gyu Seog Choi
    Jong Gwang Kim
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 1775 - 1780
  • [45] The influence of tumour mutational burden on renal cancer immune infiltration and survival
    Byrne, Matthew H. V.
    Mitchell, Thomas J.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (06)
  • [46] Clinical Significance of Local Immune Cytolytic Activity in Breast Cancer
    Kawaguchi, T.
    Qi, Q.
    Peng, X.
    Narayanan, S.
    McDonald, K.
    Liu, S.
    Yan, L.
    Takabe, K.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S13 - S13
  • [47] Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
    Hodges, Tiffany R.
    Ott, Martina
    Xiu, Joanne
    Gatalica, Zoran
    Swensen, Jeff
    Zhou, Shouhao
    Huse, Jason T.
    de Groot, John
    Li, Shulin
    Overwijk, Willem W.
    Spetzler, David
    Heimberger, Amy B.
    NEURO-ONCOLOGY, 2017, 19 (08) : 1047 - 1057
  • [48] Expression of immune checkpoints on peripheral blood cells in patients with prostate cancer
    Surdacki, Gabriel
    Sokolowska, Bozena
    Goracy, Aneta
    Chyl-Surdacka, Katarzyna
    Hus, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (04): : 219 - 225
  • [49] Clinical metric of tumor mutational burden depicts colorectal cancer patients at the extremes
    Zheng, Ming
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [50] Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy
    Winer, I.
    Jones, N. L.
    Xiu, J.
    Ellerbrock, A.
    Brown, J.
    Herzog, T.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 45 - 45